StockNews.com Upgrades Alimera Sciences (NASDAQ:ALIM) to Buy

Alimera Sciences (NASDAQ:ALIM) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Separately, Maxim Group began coverage on shares of Alimera Sciences in a report on Monday, March 25th. They issued a “buy” rating and a $10.00 price target on the stock.

Alimera Sciences Trading Up 1.4 %

NASDAQ ALIM opened at $3.59 on Monday. Alimera Sciences has a one year low of $1.56 and a one year high of $4.38. The company’s 50 day moving average price is $3.71 and its 200 day moving average price is $3.62. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39. The firm has a market capitalization of $187.94 million, a price-to-earnings ratio of -1.66 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The business had revenue of $26.31 million during the quarter, compared to analysts’ expectations of $25.10 million. During the same quarter in the previous year, the business posted ($0.54) EPS. On average, sell-side analysts predict that Alimera Sciences will post 0.03 EPS for the current year.

Institutional Trading of Alimera Sciences

Large investors have recently bought and sold shares of the company. Stonepine Capital Management LLC grew its position in shares of Alimera Sciences by 0.4% during the fourth quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock worth $17,278,000 after buying an additional 15,773 shares in the last quarter. AIGH Capital Management LLC acquired a new stake in shares of Alimera Sciences during the third quarter worth approximately $7,355,000. Finally, Worth Venture Partners LLC acquired a new stake in shares of Alimera Sciences during the third quarter worth approximately $1,840,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).